|Project Title||Principal Investigator||Institution|
|Function and dysfunction of neuroligins||Sudhof, Thomas||Stanford University|
|Genomic imbalances at the 22q11 locus and predisposition to autism||Gogos, Joseph||Columbia University|
|Genomic resources for identifying genes regulating social behavior||Young, Larry||Emory University|
|Integrated approach to the neurobiology of autism spectrum disorders||Vaccarino, Flora||Yale University|
|Investigation of the role of MET kinase in autism||Dawson, Ted||Johns Hopkins University School of Medicine|
|Mice lacking Shank postsynaptic scaffolds as an animal model of autism||Sheng, Morgan||Massachusetts Institute of Technology|
|Modeling and pharmacologic treatment of autism spectrum disorders in Drosophila||McDonald, Thomas||Albert Einstein College of Medicine of Yeshiva University|
|Molecular determinants of L-type calcium channel gating||Colecraft, Henry||Columbia University|
|Mouse genetic model of a dysregulated serotonin transporter variant associated with autism||Veenstra-Vanderweele, Jeremy||Vanderbilt University|
|Neural and cognitive mechanisms of autism||Sur, Mriganka||Massachusetts Institute of Technology|
|Neural mechanisms of social cognition and bonding||Young, Larry||Emory University|
|Neurexin-neuroligin trans-synaptic interaction in learning and memory||Kandel, Eric||Columbia University|
|Neurobiological mechanism of 15q11-13 duplication autism spectrum disorder||Anderson, Matthew||Beth Israel Deaconess Medical Center|
|Neurobiology of sociability in a mouse model system relevant to autism||Brodkin, Edward||University of Pennsylvania|
|Neurobiology of sociability in a mouse model system relevant to autism (supplement)||Brodkin, Edward||University of Pennsylvania|
|Neurogenetic model of social behavior heterogeneity in autism spectrum disorders||Platt, Michael||Duke University|
|Neurogenomics in a model for procedural learning||Hilliard, Austin||University of California, Los Angeles|
|Neuropharmacology of motivation and reinforcement in mouse models of autistic spectrum disorders||Malanga, C.J.||University of North Carolina School of Medicine|
|Novel genetic animal models of autism||Powell, Craig||University of Texas Southwestern Medical Center|
|Novel models to define the genetic basis of autism||Mills, Alea||Cold Spring Harbor Laboratory|
|Perturbed activity-dependent plasticity mechanisms in autism||Sabatini, Bernardo||Harvard Medical School|
|Primate models of autism||Amaral, David||University of California, Davis|
|Probing disrupted cortico-thalamic interactions in autism spectrum disorders||Fagiolini, Michela||Children's Hospital Boston|
|Regulation of synaptogenesis by cyclin-dependent kinase 5||Tsai, Li-Huei||Massachusetts Institute of Technology|
|Role of a novel Wnt pathway in autism spectrum disorders||Reichardt, Louis||University of California, San Francisco|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.